Peppermint Builds a Financial Ledger for Clinical Trials

Peppermint is building financial-operations infrastructure for clinical research sites and health systems. The platform connects to existing clinical trial management and accounting systems, translates study activity into billable work, reconciles payments and supports collections without asking research teams to replace the software they already use.

Co-founders David Freeman, CEO, and Vijay “VJ” Thurimella, CTO, brought payments and reconciliation experience from X1, the credit-card company Robinhood acquired in 2023. Peppermint applies that discipline to a market where every clinical trial has a different contract, schedule of events, payment process and set of exceptions.

The company matters because site capacity depends on cash flow as much as science. Research organizations can perform a patient visit correctly and still wait months to understand what they earned, what they invoiced and what a sponsor or contract research organization actually paid. Peppermint is trying to make that financial record continuous, auditable and useful enough to operate from.

About Peppermint

Peppermint serves clinical research sites and health systems that run sponsored trials. These organizations coordinate patients, investigators, protocol activity, regulatory work and sponsor relationships, but their finance teams often have to reconstruct revenue across study agreements, visit logs, invoice files and remittances that arrive in different formats and at different times.

The company positions its product as an AI back office for that work. Peppermint reads trial agreements and completed visit activity, determines what is billable, prepares invoices, matches incoming payments and identifies balances that remain open. Human billing specialists stay in the loop for exceptions and collections work that require judgment.

That combination matters. Clinical-trial billing is not a generic accounts-receivable problem. A research site needs to prove why a charge exists, connect it to the governing agreement and show how a payment maps back to the patient visit or milestone that produced it. Faster automation is valuable only if the audit trail survives.

A Financial Ledger for Clinical Trials

Peppermint integrates with systems including CRIO, Veeva, RealTime, eClinical GPS, QuickBooks, NetSuite and Sage Intacct. The product is designed to sit across clinical and financial records instead of forcing a site to move every workflow into one new application.

The operating model is continuous rather than monthly. As visits and milestones are completed, Peppermint can validate the activity against a contract and prepare the corresponding financial action. As sponsor payments arrive, the platform reconciles the remittance to the underlying work. The intended result is a live ledger showing each visit, invoice, payment and outstanding balance.

Peppermint says its partners collect revenue 3x faster, have reduced overdue invoices threefold and have reclaimed 20% of staff time previously spent on billing. The company also says the number of studies under management tripled in three months. Those are company-reported results, not independently audited performance, but they reveal the unit of value Peppermint wants customers to measure: recovered cash and returned operating time.

Leadership Built Around Reconciliation

Freeman and Thurimella met at X1 as its first business hire and first engineer. They worked on payments and reconciliation infrastructure for the consumer credit-card business that Robinhood acquired in July 2023 and later used to launch Robinhood Gold Card.

The useful connection is not that credit cards and clinical trials are the same. They are not. The connection is that both environments require a system to determine what should have happened, compare that expectation with the money that actually moved and preserve an explanation when the records disagree.

At Peppermint, Freeman owns the commercial and operating side as CEO while Thurimella leads the technical system as CTO. Current company-controlled job materials confirm both roles. Public materials reviewed for this Spotlight do not establish a reliable founding year, customer count, revenue figure or prior financing history, so those details are not treated as settled facts.

Why Research-Site Finance Is a Market

The Society for Clinical Research Sites has documented the cash pressure created by delayed receivables and limited operating cushions across the site ecosystem. Research sites carry payroll, facility and study costs while payment can depend on sponsors, contract research organizations and health systems reconciling the same work across disconnected systems.

Peppermint's website estimates that an average site network may have $240K in unbilled or under-collected revenue and wait 94 days from visit completion to sponsor payment. The company also estimates that one experienced clinical billing specialist can cost more than $120K and support only 8 to 10 active sites. These figures are Peppermint's market framing, not independent benchmarks, but they show why finance automation can become operating infrastructure rather than a small accounting convenience.

The broader shift is the professionalization of research-site operations. As sites consolidate into larger networks and health systems run more studies, spreadsheet reconciliation becomes less tolerable. A finance leader needs study-level visibility across revenue, cost, margin and cash timing, while investigators and coordinators need fewer administrative demands competing with patient work.

Funding Expands the Product Boundary

Peppermint's new $4.7M Seed round gives the company room to move beyond invoice generation and collections. Moxxie led the financing, with Homebrew, Better Tomorrow Ventures, Layout Ventures, Digital Health Venture Partners, Night Capital, Benjamin Mann and Evan Moore participating.

The next product areas are budget negotiation, expense management and clinical-trial analytics. If Peppermint can connect those functions to the same underlying evidence, a research organization could see the economics of a study before the contract is signed, while it is running and after sponsor payments arrive.

That expansion also increases the risk surface. Budgets, contracts, visit records, invoices, expenses and payments each have different sources of truth. Peppermint has to grow the product without hiding uncertainty behind an AI-generated answer. The winning system will make financial decisions faster because it preserves evidence, not because it removes review.

Hiring Shows Where Peppermint Is Building

Peppermint is actively recruiting in software engineering and AI operations. Current postings describe work on the systems that ingest operational data, automate repetitive finance tasks and manage the exceptions that do not fit a clean software path.

The software engineering role and AI operations role are useful market signals. Peppermint is not staffing only for model development or only for a services team. It is building at the boundary between software, data and human financial operations, which is where the product either becomes dependable infrastructure or another dashboard that creates follow-up work.

That is the company-level test. Peppermint has identified a costly reconciliation problem, assembled founders with relevant payments experience and shown early company-reported operating gains. Its durable advantage will depend on how accurately it learns the financial grammar of clinical trials, how well it handles exceptions and whether customers can trust the ledger as their organizations grow.

Clinical research already knows how to document scientific work. Peppermint's opportunity is to make the money behind that work just as traceable.